NMN Supplement Testing: Purity, Potency, and the Identity Problem Most Brands Haven't Solved

NMN (nicotinamide mononucleotide) is one of the most commercially explosive — and analytically underestimated — ingredients in the dietary supplement market right now. The global NAD+ precursor supplement category, of which NMN is the dominant product, has been valued at well over $300 million by multiple market research firms, with double-digit annual growth driven by a flood of longevity and cellular energy research out of institutions like Washington University in St. Louis and the University of Tokyo. Walk through any Whole Foods supplement aisle or scroll Amazon’s bestseller list and you’ll find hundreds of NMN products: 250 mg, 500 mg, “stabilized,” “sublingual,” “enteric-coated,” and a dozen other formulation claims.

The problem is that from a testing standpoint, NMN is one of the harder supplement ingredients to characterize accurately. Its chemical structure overlaps significantly with related NAD+ precursors. Its stability in finished-product matrices is genuinely tricky. And the regulatory backdrop — an active FDA determination that NMN may not qualify as a legal dietary supplement under current law — makes defensible, documented testing data more consequential than it is for most other ingredient categories.

We’ve run NMN testing panels across a wide range of supplement formats and supplier sources over the past several years, and a consistent pattern emerges: the gap between what’s on the label and what’s actually in the capsule is wider with NMN than with nearly any other trending ingredient. Here’s why that happens, and what comprehensive testing actually looks like.

Why NMN Identity Testing Is Harder Than Most Labs Make It Look

NMN sits in the middle of a biochemical pathway that includes several structurally related compounds: nicotinamide (niacinamide), nicotinamide riboside (NR), nicotinic acid mononucleotide (NAMN), and NAD+ itself. These aren’t distantly related molecules — they share significant structural features. NMN has the molecular formula C₁₁H₁₅N₂O₈P and a molecular weight of approximately 334.2 g/mol. NR, as its chloride salt, comes in at roughly 255 g/mol — meaningfully different by mass spectrometry, but not necessarily distinct under a poorly designed HPLC-UV method.

That’s the core of the identity testing problem. NMN and several of its analogs share UV absorption characteristics around 261 nm. Without mass spectrometric confirmation or a validated HPLC method that has been specifically tested for selectivity against NR, NAMN, and nicotinamide, a lab can report “NMN present” when what’s actually in the sample is a cheaper or partially degraded compound. Some contract manufacturers in markets with lower quality-control standards know this gap exists. A NMN raw material COA showing “identity confirmed” with nothing more than a UV absorption peak and a retention time from an unvalidated method is not meaningful analytical data — it’s a document.

There’s an additional chromatographic wrinkle: NMN is highly hydrophilic, which creates real retention challenges on standard reversed-phase C18 columns. Adequate retention often requires ion-pairing reagents (such as tetrabutylammonium hydrogen sulfate or ion-pairing phosphate buffers) or a shift to hydrophilic interaction liquid chromatography (HILIC). Labs that don’t have validated NMN-specific methods may be running a standard method that wasn’t developed for this compound and hoping the chromatography holds. In our experience, it frequently doesn’t hold well enough to distinguish NMN from NR in a complex supplement matrix.

Rigorous identity confirmation for NMN should include all of the following:

• Chromatographic separation using a validated HPLC method developed and demonstrated to retain NMN adequately — either with ion-pairing RP-HPLC or HILIC — not a generic small-molecule method retrofitted to NMN
• MS or MS/MS confirmation verifying the molecular ion [M+H]⁺ at m/z 335.2 and at least two characteristic fragment ions
• Selectivity demonstration against NR, NAMN, nicotinamide, and NAD+ under the same analytical conditions — this should be part of the method validation record, not an assumption
• Reference standard traceability to a characterized NMN reference standard with documented purity, ideally sourced from a recognized vendor (Sigma-Aldrich, Cayman Chemical, or equivalent)

Without all four of those elements, the identity result reflects the lab’s analytical choices more than the actual composition of your product.

Potency and the Degradation Failure Modes Brands Routinely Miss

Label claim accuracy for NMN is a documented problem across the commercially available market. Independent market testing programs — including surveys by NSF International and consumer advocacy organizations — have found NMN products ranging from below 40% to over 110% of their stated dose, with the lower end of that range heavily concentrated in products sourced from offshore contract manufacturers without robust incoming raw material testing programs.

Two degradation mechanisms drive most of the potency failures we observe in finished product testing:

Manufacturing process degradation: NMN is hygroscopic and relatively sensitive to heat and moisture. Wet granulation steps, elevated encapsulation temperatures, or prolonged exposure to humidity during processing can degrade a meaningful percentage of the active ingredient before the capsule is sealed. A brand whose label claim was established by raw material assay alone — without a finished product potency test at time of manufacture — is essentially flying blind on actual consumer dose.

Storage-phase degradation: NMN converts to nicotinamide and ribose-5-phosphate under elevated humidity and temperature conditions. An accelerated stability study run at 40°C and 75% relative humidity — standard ICH Q1B accelerated conditions — will show how quickly that conversion occurs in a specific formulation and packaging system. Products packed in non-desiccated bottles, stored in distribution centers without climate control, or sitting in mail trucks during summer will experience real NMN loss before they reach the consumer. Without 12-month real-time stability data supported by at minimum a 6-month accelerated study, a label claim is an estimate, not a verified specification.

Quantification testing should use an external standard calibration curve built from a certified-purity NMN reference standard, with the curve spanning the expected concentration range of the assay. Single-point injections against an in-house reference of unverified purity are common cost-cutting shortcuts we see on COAs from lower-tier testing providers. They’re not adequate for a finished product label claim that will be scrutinized by FDA, Amazon, or a plaintiff’s attorney.

The Regulatory Dimension — and Why It Changes the Testing Math

NMN’s regulatory status in the United States is genuinely complicated, and it substantially raises the stakes for having comprehensive testing records.

In early 2022, FDA responded to citizen petitions by concluding that NMN meets the criteria for exclusion from the dietary supplement definition under 21 U.S.C. § 321(ff)(3)(B) — the drug exclusion clause within DSHEA. The agency’s stated rationale was that NMN had been authorized for clinical investigation as a drug (for indications including acute kidney injury, among others) before it was commercially introduced as a dietary supplement. FDA cited registered clinical trials in ClinicalTrials.gov pre-dating the supplement market launch.

At the same time, FDA indicated it had not issued final guidance and intended to exercise enforcement discretion while the regulatory picture developed. Most NMN products remained on the market through 2025. But the underlying legal vulnerability didn’t go away. Brands selling NMN products operate with an ingredient that FDA has formally signaled it considers outside the legal dietary supplement definition — and that determination hasn’t been reversed.

What this means practically is that NMN brands face a level of regulatory exposure that most supplement categories don’t. In a warning letter scenario or an import alert review, the primary evidence that demonstrates a brand was operating in good faith is a documented, complete quality testing file from an ISO 17025 accredited laboratory. Vague COAs from overseas suppliers, identity results from unvalidated methods, and the absence of stability data won’t hold up under scrutiny.

The testing package we put together for NMN products at minimum covers five areas:

1. Raw material identity (HPLC with MS confirmation) from each new lot of NMN ingredient, tested before manufacture begins — not accepted on the supplier’s COA alone
2. Finished product potency assay at time of manufacture, against a traceable NMN reference standard
3. Accelerated stability data at 40°C/75% RH, with at least 6-month timepoints and a commitment to real-time stability through shelf-life
4. Microbial limits testing per USP <61> and <62> for total aerobic count, yeast and mold, and specified organisms
5. Heavy metals panel by ICP-MS — lead, arsenic, mercury, and cadmium — benchmarked against Prop 65 warning thresholds if the product is sold in California

That’s five analytical panels, and we’d argue all five are non-optional given the category’s regulatory profile.

What to Ask Your NMN Supplier — Before You Accept the Next Lot

The NMN raw material supply chain runs heavily through manufacturers in China, South Korea, and a small number of other Asian markets. Supplier quality varies enormously, and that variation isn’t always visible in a COA that looks professional.

When evaluating an NMN raw material supplier, ask for the actual analytical method used for identity confirmation — not just the COA, but the method document. Ask specifically whether the method was validated for selectivity against NR and NAMN. Ask for the reference standard certificate of analysis, including purity percentage and expiration date. If the supplier can’t produce those three documents on request, that’s diagnostic information about their quality system.

Even from a supplier with a strong track record, we recommend incoming raw material testing on every new lot until you’ve accumulated enough data to implement a skip-testing program with statistical confidence. A single lot of substituted or degraded NMN reaching finished product — and triggering an Amazon complaint that leads to third-party testing — can create regulatory and reputational damage that takes far longer to recover from than the cost of routine incoming testing.

NMN is a genuinely interesting ingredient. The NAD+ precursor research is real and the consumer interest is legitimate. The brands that will own this category long-term are the ones who can defend their quality data with confidence. That’s not speculation — it’s the same pattern we saw play out in fish oil through the TOTOX transparency shift, in probiotics through the CFU viability debate, and in collagen through the peptide authenticity reckoning. Testing gets serious in every category eventually. In NMN, it’s already here.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• FDA 21 CFR Part 111 GMP Audit Readiness for Supplement Brands — Aurora TIC covers the regulatory strategy and documentation framework supplement brands need when FDA scrutiny intensifies — directly relevant to NMN’s current enforcement environment.
• NHP Raw Material and Supplier Qualification Testing in Canada — Androxa outlines Health Canada’s NHP requirements for NAD+ precursor ingredients, including identity verification and supplier qualification under Canadian GMP.
• Global Raw Material COA Verification and Supplier Testing Programs — Ayah Labs covers the independent raw material testing programs brands use to verify overseas NMN and NAD+ precursor supplier claims before manufacturing begins.